---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035082"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:02:42.115501+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio enters securities purchase agreement for $1.025M common stock offering

## Summary
- Sold 114,911 shares at $8.92/share to institutional investor for gross proceeds of $1,025,000.
- Issued under effective shelf registration statement on Form S-3 (333-276814) effective Feb 12, 2024.
- Closing expected promptly after conditions satisfied, including NYSE listing of the shares.
- 30-day lock-up restricts additional equity issuances, warrant amendments, and variable rate transactions.

## SEC filing metadata
- accession: 0001104659-24-035082
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/0001104659-24-035082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/tm248952d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035082
- JSON: https://secwatch.observer/filing/0001104659-24-035082.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035082.txt

## Key facts
- Material Agreements
  Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds of $1,025,000 (effective 2024-03-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: aggregate gross proceeds of $1,025,000
  - Effective: 2024-03-15
  source text: On March 15, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/0001104659-24-035082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.